GSK (NYSE:GSK) Updates FY 2026 Earnings Guidance

GSK (NYSE:GSK) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 4.900-5.000 for the period, compared to the consensus estimate of 4.790. The company issued revenue guidance of $44.8 billion-$44.8 billion, compared to the consensus revenue estimate of $45.7 billion. GSK also updated its FY 2031 guidance to EPS.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on GSK shares. Weiss Ratings cut GSK from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 11th. Jefferies Financial Group raised shares of GSK to a “strong-buy” rating in a research note on Friday, July 17th. Citigroup started coverage on GSK in a report on Friday, July 24th. They issued a “neutral” rating on the stock. Wall Street Zen upgraded shares of GSK from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of GSK in a research report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $53.00.

GSK Stock Down 1.7%

Shares of NYSE:GSK traded down $0.89 on Thursday, hitting $52.33. 1,062,025 shares of the company’s stock were exchanged, compared to its average volume of 4,680,948. The firm’s 50-day moving average is $51.72 and its 200 day moving average is $53.48. The company has a market capitalization of $105.84 billion, a PE ratio of 16.46, a P/E/G ratio of 3.42 and a beta of 0.35. GSK has a 1-year low of $36.75 and a 1-year high of $61.69. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.52 and a current ratio of 0.79.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be given a $0.4515 dividend. This represents a $1.81 dividend on an annualized basis and a yield of 3.5%. This is a boost from GSK’s previous quarterly dividend of $0.44. The ex-dividend date of this dividend is Friday, August 14th. GSK’s dividend payout ratio is presently 46.49%.

Institutional Investors Weigh In On GSK

Several hedge funds have recently modified their holdings of GSK. Align Financial LLC purchased a new stake in shares of GSK in the fourth quarter valued at approximately $5,628,000. Arkadios Wealth Advisors lifted its holdings in GSK by 59.0% in the fourth quarter. Arkadios Wealth Advisors now owns 107,379 shares of the pharmaceutical company’s stock valued at $5,266,000 after acquiring an additional 39,863 shares during the period. BI Asset Management Fondsmaeglerselskab A S boosted its position in shares of GSK by 28.2% during the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 121,249 shares of the pharmaceutical company’s stock worth $4,656,000 after purchasing an additional 26,685 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of GSK by 84.4% during the 1st quarter. AQR Capital Management LLC now owns 40,239 shares of the pharmaceutical company’s stock worth $1,559,000 after purchasing an additional 18,420 shares in the last quarter. Finally, Brighton Jones LLC acquired a new position in shares of GSK during the 4th quarter worth $528,000. 15.74% of the stock is owned by institutional investors and hedge funds.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.